Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial-Reference-Cited by-同舟云学术

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

Published:2012-03-22 Issue:7 Volume:71 Page:1212-1215
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Song In-Ho,Althoff Christian E,Haibel Hildrun,Hermann Kay-Geert A,Poddubnyy Denis,Listing Joachim,Weiß Anja,Djacenko Svetlana,Burmester Gerd R,Bohl-Bühler Martin,Freundlich Bruce,Rudwaleit Martin,Sieper Joachim

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings);Current Rheumatology Reports;2024-02-09

2. Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis;The Journal of Rheumatology;2023-10-15

3. To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question;Best Practice & Research Clinical Rheumatology;2023-09

4. Potential for sustaining remission in ankylosing spondylitis patients upon netakimab discontinuation;Meditsinskiy sovet = Medical Council;2023-07-24

5. Décroissance ou arrêt des traitements de fond biologiques dans la spondyloarthrite axiale : revue de la littérature;Revue du Rhumatisme;2023-05